We examine the trend for increasing and more transparent patient information and ask how close we have come in the last few years to producing useful and meaningful information for patients. We also outline the challenges faced by medical writers and the pharmaceutical industry as a whole in trying to comply with recent European require - ments for the creation of lay summaries of key regulatory submission documents. The risk management plan and the results section describe outcomes of clinical trials – and what this means for patients – who are the target audience that this monumental effort is intended to help.
Editor-in-Chief:
Co-Editor:
Managing Editor
Associate Editors:
Section Editors:
Ad-hoc Editors:
Editor Emeritus: